Drug profile · INN
satralizumab
ENSPRYNG
satralizumab (ENSPRYNG) is a il6ralpha/gp130 antagonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — satralizumab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- INJECTION
- Patents
- 0
- Programs
- 7
- Data quality
- 0.84
Quick answer
satralizumab (ENSPRYNG) is a il6ralpha/gp130 antagonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
IL6Ralpha/GP130 antagonist
Primary target: IL6Ralpha/GP130
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is satralizumab?
satralizumab (ENSPRYNG) is a il6ralpha/gp130 antagonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for satralizumab?
ENSPRYNG is a marketed brand name for satralizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of satralizumab?
satralizumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.